Renpress, Sandopril (Spirapril/TI 211-950). Summary of chemical, pharmacological and clinical properties.
Jerie
P
P
Cardiovascular Department, Sandoz Pharma Ltd., Basle, Switzerland.
Kremer
H J
HJ
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D004656:Enalapril / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate
D000806:Angiotensin-Converting Enzyme Inhibitors; D004656:Enalapril; C052555:spirapril